Frequency of rare BCR‐ABL1 fusion transcripts in chronic myeloid leukemia patients
- 29 December 2016
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 39 (3), 235-242
- https://doi.org/10.1111/ijlh.12616
Abstract
Introduction The hallmark of chronic myeloid leukemia (CML) is the presence of Philadelphia chromosome, its resultant fusion transcript (BCR‐ABL1), and fusion protein (p210). Alternate breakpoints in BCR (m‐bcr, μ‐bcr, and others) or ABL1 result in the expression of few rare fusion transcripts (e19a2, e1a2, e13a3, e14a3) and fusion proteins (p190, p200, p225) whose exact clinical significance remains to be determined. Methods Our study was designed to determine the type and frequency of BCR‐ABL1 fusion transcripts in 1260 CML patients and to analyze the prognosis and treatment response in patients harboring rare BCR‐ABL1 fusion transcripts. Results The frequency of various BCR‐ABL1 fusion transcripts was as follows: e14a2 (60%), e13a2 (34.3%), e1a2 (1.2%), e1a2 + e13a2 (2.0%), e1a2 + e14a2 (1.8%), e19a2 (0.3%), and e14a3 (0.3%). CML patients with e1a2 transcripts had higher rates of disease progression, resistance, or suboptimal response to imatinib and failed to achieve major molecular response. Conclusion Characterization of the specific fusion transcript in CML patients is important owing to the difference in prognosis and response to therapy in addition to the conventional need for monitoring treatment response. CML patients with e1a2 transcripts have to be closely monitored due to the high incidence of disease progression and treatment resistance/failure.Keywords
Funding Information
- Department of Biotechnology India (BT/COE/34/SP13432/2015.)
- Wellcome DBT India Alliance (IA/S/11/2500267, IA/S/15/1/501842)
This publication has 34 references indexed in Scilit:
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreBlood, 2011
- Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patientsGenetics and Molecular Biology, 2010
- Spectrum ofBCR-ABLkinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributionsLeukemia & Lymphoma, 2009
- Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysisBlood, 2009
- Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcriptHaematologica, 2009
- A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia: Diagnostic Challenges in Clinical Laboratory PracticeThe Journal of Molecular Diagnostics, 2009
- E6a2BCR-ABLfusion withBCRexon 5-deleted transcript in a Philadelphia positive CML responsive to ImatinibLeukemia & Lymphoma, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Insertion of a genomic fragment of chromosome 19 between BCR intron 19 and ABL intron 1a in a chronic myeloid leukaemia patient with μ‐BCR‐ABL (e19a2) transcriptBritish Journal of Haematology, 2004
- B3/A3 Rearrangement in a Patient with Chronic Myeloid LeukemiaLeukemia & Lymphoma, 2003